OBJECTIVES: V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes eight unique serotypes (15A, 15C [generated from deOAc-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine. According to the CDC data from 2018-2021, the serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease (IPD) in individuals aged 65+, and the unique 8 serotypes were responsible for approximately 30%. This study estimates the potential health and economic impact of vaccination with V116 vs. PCV20 on IPD in the US adults aged 50+.

METHODS: A Markov model was built to estimate the lifetime IPD cases, IPD related deaths, and the associated direct and indirect medical costs among the current US adults aged 50-64 and 65+ (assuming 2021 population figures) vaccinating with V116 or PCV20. The same serotype specific vaccine effectiveness, and the same vaccine coverage rates (55.2%) were assumed for the two vaccines.

RESULTS: In adults aged 50-64, V116 prevented 26,999 IPD cases and 3,094 IPD deaths – 57% more than the 17,149 IPD cases and 1,963 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in $1.2 billion reduction in total medical costs (both direct and indirect) – 53% higher than the $0.77 billion costs averted by PCV20.

In adults aged 65+, V116 prevented 33,561 IPD cases and 4,852 IPD deaths – 74% more than the 19,311 IPD cases and 2,791 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in $841 million reduction in total medical costs (both direct and indirect) –74% higher than the $484 million costs averted by PCV20.

CONCLUSIONS: In both age groups, comparing with PCV20, V116 led to a greater reduction of both the health and economic burden associated with IPD.